Simple Summary
Drugs originally developed for non-cancer conditions are being investigated as potential cancer treatments. We reviewed selected clinical studies reported between 1 January 2021 and 31 July 2026, including positive and negative findings. In the settings studied, metformin, nelfinavir, disulfiram, losartan, and propofol-based anesthesia generally did not improve major outcomes. By contrast, aspirin reduced recurrence in colorectal cancer with specific genetic alterations, while local lidocaine administered before breast cancer surgery improved survival outcomes. Small trials of pharmacological ascorbate in pancreatic cancer and simvastatin in recurrent small-cell lung cancer showed encouraging but unconfirmed results. Overall, effective drug repurposing requires adequate drug exposure, evidence that the proposed biological target is affected, careful patient selection, and confirmation in well-designed randomized trials. Benefits observed in one patient group or treatment setting should not be assumed to apply to other cancers.
Abstract
Drug repurposing builds on pharmacological and safety information already available for an approved drug, but this advantage requires additional studies to establish the biological effect and related mechanisms of action. We conducted a clinically focused review of non-oncology drugs tested as active cancer treatments in interventional studies from 1 January 2021 to 31 July 2026. Randomized trials, phase II–III studies, biomarker-selected cohorts, and studies reporting pharmacokinetics or human target engagement were prioritized. Despite the large number of registered studies, the landscape is still dominated by early-phase, academically sponsored trials. Several widely studied candidates, including metformin, nelfinavir, disulfiram–copper, losartan, and propofol, were negative in randomized evaluations. Conversely, aspirin reduced recurrence in localized colorectal cancer with PI3K-pathway alterations, while preoperative peritumoral lidocaine administration was associated with improved disease-free survival and overall survival in a randomized breast cancer trial. Smaller randomized trials investigating pharmacological ascorbate in pancreatic cancer and simvastatin in recurrent small-cell lung cancer provided preliminary efficacy signals that require confirmation in larger studies. Across drug classes, unsuccessful programs were often limited by inadequate exposure, uncertain tumor penetration, absent pharmacodynamic evidence, heterogeneous patient populations, or weak continuity between exploratory and confirmatory development. Progress will depend on more selective clinical hypotheses, early demonstration of human pharmacology, prospective biomarkers, and clear regulatory ownership.